DXR (Daxor Corp.) היקף נכסי החברה

Daxor Corporation (DXR) is expanding its business in the field of precision blood volume monitoring, ensuring stable sales of equipment for cardiologists and intensive care specialists. The company acts as an industry pioneer, offering the BVA-100, the only FDA-certified device for the rapid detection of occult heart failure. This price chart illustrates total assets at 43.87, as the firm implements automated plants and cloud-based AI software.

Scaling the logistics network of Daxor Corporation (DXR) for the delivery of precision blood monitoring devices requires significant capital expenditures in infrastructure. This metric, calculated inversely via ROA, aggregates the value of all resources and liabilities, allowing investors to assess financial stability and over-leverage risk when analyzing total assets through ROA.